title: Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients.
abstract: BACKGROUND
  Radiofrequency (RF) energy delivery is an endoscopic procedure developed for the treatment of gastro-oesophageal reflux disease.
  
  
  OBJECTIVE
  To compare RF and a proton pump inhibitor strategy (PPI) in PPI-dependent patients by carrying out a prospective, randomized trial.
  
  
  METHODS
  Patients with PPI-dependent typical reflux symptoms were randomly allocated to either RF or PPI regimen alone. The primary endpoint, evaluated at 6-month, was defined as the possibility for the patient to stop or to decrease PPI use to <50% of the effective dose required at baseline.
  
  
  RESULTS
  In the RF group, 18/20 patients stopped (n = 3) or decreased (n = 15) PPI use as compared to eight of 16 in the PPI group (P = 0.01). None of the control patients could stop PPI. Health-related quality of life scores were not different between groups. No significant change in oesophageal acid exposure (OAE) was noted between baseline and 6-months after RF. No severe complication was reported.
  
  
  CONCLUSIONS
  Radiofrequency energy delivery is a safe and effective therapeutic option, allowing reduction in or discontinuation of PPI therapy in patients with PPI-dependent symptoms, without loss of quality of life. However, in a majority of patients, PPI therapy cannot be completely stopped. The efficacy of RF does not seem to be related to a decrease in OAE.
authors.affiliation: Institut des Maladies de l'Appareil Digestif, CHU Hôtel-Dieu, Nantes.
authors.forename: E
authors.initials: E
authors.lastname: Coron
authors.forename: V
authors.initials: V
authors.lastname: Sebille
authors.forename: G
authors.initials: G
authors.lastname: Cadiot
authors.forename: F
authors.initials: F
authors.lastname: Zerbib
authors.forename: P
authors.initials: P
authors.lastname: Ducrotte
authors.forename: F
authors.initials: F
authors.lastname: Ducrot
authors.forename: P
authors.initials: P
authors.lastname: Pouderoux
authors.forename: J
authors.initials: J
authors.lastname: Arts
authors.forename: M
authors.initials: M
authors.lastname: Le Rhun
authors.forename: T
authors.initials: T
authors.lastname: Piche
authors.forename: S
authors.initials: S
authors.lastname: Bruley des Varannes
authors.forename: J P
authors.initials: JP
authors.lastname: Galmiche
mesh_terms: D000328:Adult; D017115:Catheter Ablation / Q000379:methods*; D016099:Endoscopy, Gastrointestinal / Q000379:methods; D050782:Esophageal pH Monitoring; D005260:Female; D005764:Gastroesophageal Reflux / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D011788:Quality of Life; D012720:Severity of Illness Index; D013223:Statistics as Topic
chemical_list: D054328:Proton Pump Inhibitors